IBPM 004AM

Drug Profile

IBPM 004AM

Alternative Names: IBPM004AM; IBPM004AM (biosimilar) - Inbiopro Solutions

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inbiopro Solutions
  • Class Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ankylosing-spondylitis in India (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in India (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Juvenile-rheumatoid-arthritis in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top